Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report

After the approval of the first vaccines against SARS-CoV-2, a mass vaccination is currently being performed worldwide. Despite the safety and efficacy of such drugs evidenced by the registration studies, no clinical trial has to date included patients affected by autoimmune diseases nor data coming from real life are currently available. In this regard, we report the case of a patient affected by microscopic polyangiitis who suspended Methotrexate prior to vaccination and relapsed after the administration of the first dosage. The patient required hospitalization and was treated with high dosages of steroids but was rapidly discharged in good clinical condition. Our case evidences that the immune response triggered by the administration of the vaccine against COVID 19 may reactivate autoimmune disorders, but such condition seems manageable and the withdrawal of the immunosuppressants should not be performed. This article is protected by copyright. All rights reserved.